IRB #

STUDY00018253

Title

A Phase 1, Open-label, Study of Voruciclib in Subjects with Relapsed and/or Refractory B Cell Malignancies or Acute Myeloid Leukemia After Failure of Prior Standard Therapies

Principal Investigator

Alexey Danilov

Study Purpose

The purpose of this study is to see what effects, good or bad, the experimental drug voruciclib has on patients with relapsed (cancer returned after previous treatment regimen) and/or refractory (cancer did not respond to previous treatment regimen) B cell malignancies such as follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), or acute myeloid leukemia (AML).

Medical Condition(s)

Relapsed and/or refractory follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), and acute myeloid leukemia (AML)

Eligibility Criteria

- Men and women at least 18 years of age who have FL, MCL, MZL, SLL, CLL, DLBCL, or AML
- You must have disease that has relapsed or is refractory to 2 or more prior treatment regimens and you are in need of treatment due to progressive disease
- You must have received all appropriate standard of care therapy for your disease and have developed disease progression or are intolerant to appropriate standard of care therapy

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

You will get the study drug for as long as you are benefiting from treatment, or until your disease gets worse or the side effects become too severe.

Minors Included

No

Contact

Clinical Trials Information Line
Phone: 503-494-1080
Email: trials@ohsu.edu

Sponsor

MEI Pharma, Inc.

Recruitment End

03/01/2022

Compensation Provided

No


Go Back